11/1/16 - 10%; PI Baer) “A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.” Van Andel-SU2C, Inc. Clinical Trials: ~$1.390M Rassool lab $156,342.0 Role: Provide correlative studies for clinical trial. 07/01/17 - 6/30/19 (PI, 10%) “Mechanisms for sensitivity to HDAC inhibitors involving PARP trapping in leukemias” NIH - R21 Annual Direct Costs: $150,000 Total Direct Costs: $375,000 Pending Grants University of Maryland – 7/01/17 - 11/30/22 (PI, 10%) underlying the efficacy of PARP inhibitors and DNA demethylating “Mechanisms agents in triple negative breast cancer,” NIH R01 – Annual Direct Costs: $250,000 Direct 000 This grant will be reviewed in February 13 2017 Completed Grants University of Chicago – 01/96 - 01/97 (PI, 10%) FHIT gene and FRA3B in Breast Cancer” “The NCI Breast Cancer Pilot Grant Total Direct Costs: $35,000 01/97 - 01/98 (PI, 10%) FRA3B in Ductal Carcinoma of the Breast” “The Blowitz-Ridgeway Award, American Cancer Society (Illinois) Direct Costs: $35,000 Completed Grants King’s College, London, UK – 09/98 - 09/01 (PI, 100%) Instability in Myelodysplastic Syndromes (I)” “Genomic Elimination of Leukaemia Fund, UK (Private Foundation) Total Direct Costs: $699,090
11/1/16 - 10%; PI Baer) “A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patients with Intermediate or High-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.” Van Andel-SU2C, Inc. Clinical Trials: ~$1.390M Rassool lab $156,342.0 Role: Provide correlative studies for clinical trial. 07/01/17 - 6/30/19 (PI, 10%) “Mechanisms for sensitivity to HDAC inhibitors involving PARP trapping in leukemias” NIH - R21 Annual Direct Costs: $150,000 Total Direct Costs: $375,000 Pending Grants – University of Maryland 7/01/17 - 11/30/22 (PI, 10%) “Mechanisms underlying the efficacy of PARP inhibitors and DNA demethylating agents in triple negative breast cancer,” NIH – R01 Annual Direct Costs: $250,000 Direct 000 This grant will be reviewed in February 13 2017 Completed Grants – University of Chicago 01/96 - 01/97 (PI, 10%) “The FHIT gene and FRA3B in Breast Cancer” NCI Breast Cancer Pilot Grant Total Direct Costs: $35,000 01/97 - 01/98 (PI, 10%) “The FRA3B in Ductal Carcinoma of the Breast” Blowitz-Ridgeway Award, American Cancer Society (Illinois) Direct Costs: $35,000 Completed Grants – King’s College, London, UK 09/98 - 09/01 (PI, 100%) “Genomic Instability in Myelodysplastic Syndromes (I)” Elimination of Leukaemia Fund, UK (Private Foundation) Total Direct Costs: $699,090
Rassool-CV-updated--February-2017.docx